COMPARATIVE STUDY OF MICROALBUMINURIA AND GLYCATED HEMOGLOBIN LEVELS IN TYPE 2 DIABETIC COMPLICATIONS

  • Gunjan Kumar Mandal
  • Jyothrimayi D

Abstract

ABSTRACT
Objective: Microalbuminuria occurs when the kidney leaks a small amount of albumin into the urine or when there is an abnormally high permeability
for albumin in the renal glomerulus. Microalbuminuria is a powerful risk factor of cardiovascular disease and for the presence and severity of diabetic
retinopathy and neuropathy. The aim of this study is to compare the levels of microalbumin and glycated hemoglobin (HbA1c) levels in Type 2 diabetic
complications.
Methods: The study includes 100 patients with Type 2 diabetes mellitus visiting the diabetic out-patient department patients with complications,
such as hypertension, retinopathy, neuropathy, and cardiovascular complication, was diagnosed based on history and clinical examination and related
investigations. Microalbuminuria levels and HbA1c levels are compared in patients with complications (subjects) of Type 2 diabetes mellitus and
patients without complications.
Results: The study revealed that microalbumin levels are at a significantly higher range with high HbA1c levels in patients with complications
(p<0.05). When compared to patients without complications.
Conclusion: The study supports that strict glycemic control can prevent microalbuminuria and thereby prevent progress on to diabetic nephropathy
in patients with Type 2 diabetes mellitus.
Keywords: Microalbuminuria, Glycated hemoglobin, Diabetic complications

References

REFERENCES
1. Prasad KD, Rajaseker P. Study of micro albuminuria as a cardiovascular
risk factor in type diabetes mellitus. Iran J Kidney Dis 2012;3(1):12-6.
2. Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe
NR, et al. Meta-analysis: Glycosylated hemoglobin and cardiovascular
disease in diabetes mellitus. Ann Intern Med 2004;141(6):421-31.
3. Powers AC. Diabetes mellitus. In: Kasper DL, Braunwald E, Fauci AS,
Hauser SL, Longo DL, Jameson JL, editors. Harrison’s Principles of
Internal Medicine. 16
ed. USA: The McGraw Hill Companies Inc.;
2005. p. 2152-80.
th
4. Taylor R. Practical community screening for diabetic retinopathy
using the mobile retinal camera: Report of a 12 centre study. British
diabetic association mobile retinal screening group. Diabet Med
1996;13(11):946-52.
5. Balasubramanyam M, Rema M, Premanand C. Biochemical and
molecular mechanism of diabetic retinopathy. Curr Sci 2002;83:1507-13.
6. Rema M, Ponnaiya M, Mohan V. Prevalence of retinopathy in noninsulin
dependent
diabetes
mellitus
at
a
diabetes
centre
in
southern

India.
Diabetes Res Clin Pract 1996;34(4):29-36.
7. Rema M, Deepa R, Mohan V. Prevalence of retinopathy at diagnosis
among Type 2 diabetic patients attending a diabetic centre in South
India. Br J Ophthalmol 2000;84(9):1058-60.
8. Gardner TW, Aiello P. Biochemical and molecular mechanism of
diadetic. Am Acad Opthalmol Monogr 2000;14:1-18.
9. Root HF, Pote WH Jr, Frehner H. Triopathy of diabetes; sequence of
neuropathy, retinopathy, and nephropathy in one hundred fifty-five
patients. AMA Arch Intern Med 1954;94(6):931-41.
10. Boulton AJ, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R,
et al. Diabetic neuropathies: A statement by the American Diabetes
Association. Diabetes Care 2005;28(4):956-62.
11. Boulton AJ, Malik RA, Arezzo JC, Sosenko JM. Diabetic somatic
neuropathies. Diabetes Care 2004;27(6):1458-86.
12. Thomas FP. The spectrum of diabetic neuropathy. Phys Med Rehabil
Clin N Am 2008;19(1):1-v.
13. Abbott CA, Carrington AL, Ashe H, Bath S, Every LC, Griffiths J, et al.
The North-West diabetes foot care study: Incidence of, and risk factors
for, new diabetic foot ulceration in a community-based patient cohort.
Diabet Med 2002;19(5):377-84.
14. Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H. Mortality and
causes of death in the WHO multinational study of vascular disease in
diabetes. Diabetologia 2001;44 Suppl 2:S14-21.
15. Cea-Calvo L, Conthe P, Gómez-Fernández P, de Alvaro F, FernándezPérez
C; Richard Investigators. Target
organ
damage and cardiovascular
complications
in
patients with
hypertension and
Type
2
diabetes in

359
Asian J Pharm Clin Res, Vol 9, Issue 2, 2016, 356-360
Mandal and Jyothrimayi
Spain: A cross-sectional study. Cardiovasc Diabetol 2006;5:23.
16. Palatini P, Mormino P, Mos L, Mazzer A, Dorigatti F, Zanata G, et al.
Micro albuminuria, renal function and development of sustained
hypertension: A longitudinal study in the early stage of hypertension.
J Hypertens 2005;23(1):175-82.
17. Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR,
et al. Risk factors for coronary artery disease in non-insulin dependent
diabetes mellitus: United Kingdom Prospective Diabetes Study
(UKPDS: 23). BMJ 1998;316(7134):823-8.
18. Bell DS. Treatment of diabetic hypertension. Diabetes Obes Metab
2009;11(5):433-44.
19. Sever PS, Poulter NR, Dahlof B, Wedel H, Beevers G, Caulfield M,
et al. The Anglo-Scandinavian cardiac outcomes trial lipid lowering
arm: Extended observations 2 years after trial closure. Eur Heart J
2008;29(4):499-508.
20. Bouhanick B, Berrut G, Chameau AM, Hallar M, Bled F, Chevet B,
et al. Predictive value of testing random urine sample to detect micro
albuminuria in diabetic subjects during outpatient visit. Diabete Metab
1992;18(1):54-8.
21. Ruggenenti P, Remuzzi G. Nephropathy of Type 2 diabetes mellitus.
J Am Soc Nephrol 1998;9(11):2157-69.
22. Al Shaikh A. Prevalence of micro albuminuria in Type 2 diabetes
mellitus at a diabetic clinic in King Abdul-Aziz University Hospital.
Pak Med Sci 2007;23:223-6.
23. Nathan DM, Turgeon H, Regan S. Relationship between glycated
haemoglobin levels and mean glucose levels over time. Diabetologia
2007;50(11):2239-44.
24. International Expert Committee. International Expert Committee report
on the role of the A1
assay in the diagnosis of diabetes. Diabetes Care
2009;32(7):1327-34.
C
25. Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ; AcDerived
Average
Glucose
Study
Group. Translating
the
A1
assay into
estimated average glucose values. Diabetes Care 2008;31(8):1473-8.
26. American Diabetes Association. Cardiovascular risk factor and disease
management in Type 2 diabetes with diabetes nephropathy. Diabetes
Care 2006;29(3):498-503.
27. Parving HH, Lewis JB, Ravid M, Remuzzi G, Hunsicker LG; DEMAND
Investigators. Prevalence and risk factors for micro albuminuria in
a referred cohort of Type 2 diabetic patients: A global perspective.
Kidney Int 2006;69(11):2057-63.
28. Gupta DK, Verma LK, Khosla PK, Dash SC. The prevalence of micro
albuminuria in diabetes: A study from north India. Diabetes Res Clin
Pract 1991;12(2):125-8.
29. Singh SK, Behre A, Singh MK. Diabetic retinopathy and micro
albuminuria in lean Type 2 diabetes mellitus. J Assoc Physicians India
C
2001;49:439-41.
30. Mohan V, Meera R, Premalatha G, Deepa R, Miranda P, Rema M.
Frequency of proteinuria in Type 2 diabetes mellitus seen at a diabetes
centre in Southern India. Postgrad Med J 2000;76(899):569-73.
31. Klein R, Klein BE, Moss SE. Prevalence of micro albuminuria in olderonset
diabetes. Diabetes Care 1993;16(10):1325-30.
32. Haffner SM, Morales PA, Gruber MK, Hazuda HP, Stern MP.
Cardiovascular risk factors in non-insulin-dependent diabetic subjects
with micro albuminuria. Arterioscler Thromb 1993;13(2):205-10.
33. John L, Rao PS, Kanagasabapathy AS. Prevalence of diabetic
nephropathy in non-insulin dependent diabetics. Indian J Med Res
1991;94:24-9.
34. Florkowski CM, Jennings PE, Rowe B, Lawson N, Nightingale S,
Barnett AH. Micro albuminuria in diabetic subjects with chronic
peripheral neuropathy. Diabetes Res Clin Pract 1988;5(1):45-8.
35. Parving HH, Hommel E, Mathiesen E, Skøtt P, Edsberg B, Bahnsen M,
et al. Prevalence of micro albuminuria, arterial hypertension, retinopathy
and neuropathy in patients with insulin dependent diabetes. Br Med J
(Clin Res Ed) 1988;296(6616):156-60.
36. Young RJ, Maclntyre CC, Martyn CN, Prescott RJ, Ewing DJ,
Smith AF, et al. Progression subclinical polyneuropathy in young
patients with - Type 1 (insulin-dependent) diabetes: Associations with
glycemic control and microangiopathy (microvascular complications).
Diabetologia 1969;29:156-61.
37. Bigazzi R, Bianchi S. Micro albuminuria as a marker of cardiovascular
and renal disease in essential hypertension. Nephrol Dial Transplant
1995;10 Suppl 6:10-4.
38. Pontremoli R. Micro albuminuria in essential hypertension – its
relation to cardiovascular risk factors. Nephrol Dial Transplant
1996;11(11):2113-5.
39. Pontremoli R, Sofia A, Ravera M, Nicolella C, Viazzi F, Tirotta A,
et al. Prevalence and clinical correlates of micro albuminuria in
essential hypertension: The magic study. Micro albuminuria: A genoa
investigation on complications. Hypertension 1997;30(5):1135-43.
40. Schmitz A. Micro albuminuria, blood pressure, metabolic control, and
renal involvement: Longitudinal studies in white non-insulin-dependent
diabetic patients. Am J Hypertens 1997;10:189S-97.
41. Stehouwer CD, Lambert J, Donker AJ, van Hinsbergh VW. Endothelial
dysfunction and pathogenesis of diabetic angiopathy. Cardiovasc Res
1997;34(1):55-68.
42. Bakris GL. Micro albuminuria: Prognostic implications. Curr Opin
Nephrol Hypertens 1996;5(3):219-23.
43. Mogyorósi A, Ziyadeh FN. Update on pathogenesis, markers and
management of diabetic nephropathy. Curr Opin Nephrol Hypertens
1996;5(3):243-53.
360
Statistics
333 Views | 1687 Downloads
How to Cite
Mandal, G. K., and J. D. “COMPARATIVE STUDY OF MICROALBUMINURIA AND GLYCATED HEMOGLOBIN LEVELS IN TYPE 2 DIABETIC COMPLICATIONS”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 9, no. 2, Mar. 2016, pp. 356-60, https://innovareacademics.in/journals/index.php/ajpcr/article/view/10920.
Section
Original Article(s)